Modified prosthetic vascular conduits

Circulation

Volumn 117, Issue 14, 2008, Pages 1873-1882

  Kapadia, Muneera R ^a   Popowich, Daniel A ^a   Kibbe, Melina R ^a,b  

^a NORTHWESTERN UNIVERSITY   (United States)

^b NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Atherosclerosis; Bypass; Peripheral vascular disease; Restenosis; Revascularization

Indexed keywords

ANTICOAGULANT AGENT; ELASTIN; FIBROBLAST GROWTH FACTOR; HEPARIN; HIRUDIN; ILOPROST; MACROGOL; NITRIC OXIDE; PACLITAXEL; POLITEF; POLYETHYLENE TEREPHTHALATE; RAPAMYCIN; THROMBOMODULIN; TISSUE PLASMINOGEN ACTIVATOR;

BYPASS SURGERY; CLINICAL TRIAL; DACRON IMPLANT; DRUG ELUTING STENT; DRUG HALF LIFE; DRUG RELEASE; ENDOTHELIUM CELL; FEMOROPOPLITEAL BYPASS; GRAFT FAILURE; GRAFT PATENCY; HUMAN; MATERIAL COATING; NONHUMAN; PRIORITY JOURNAL; PROSTHESIS MATERIAL; RESTENOSIS; REVIEW; SAPHENOUS VEIN GRAFT; THROMBOSIS; VASCULAR PATENCY;

ANIMALS; ANTICOAGULANTS; BIOCOMPATIBLE MATERIALS; BLOOD VESSEL PROSTHESIS; BLOOD VESSEL PROSTHESIS IMPLANTATION; CLINICAL TRIALS AS TOPIC; COATED MATERIALS, BIOCOMPATIBLE; DRUG IMPLANTS; ENDOTHELIAL CELLS; EQUIPMENT DESIGN; EQUIPMENT FAILURE; GRAFT OCCLUSION, VASCULAR; HUMANS; NITRIC OXIDE DONORS; POLYTETRAFLUOROETHYLENE; POLYURETHANES; POSTOPERATIVE COMPLICATIONS; RETROSPECTIVE STUDIES; TRANSPLANTATION, AUTOLOGOUS;

EID: 41949117318     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.107.714170     Document Type: Review

References (65)

1. Veith FJ, Gupta SK, Ascer E, Whiteflores S, Samson RH, Scher LA, Towne JB, Bernhard VM, Bonier P, Flinn WR, Astelford P, Yao JST, Bergan JJ. 6-Year prospective multicenter randomized comparison of autologous saphenous-vein and expanded polytetrafluoroethylene grafts in infrainguinal arterial reconstructions. J Vasc Surg. 1986;3:104-114.
2. Friedman SG. History of Vascular Surgery. 2nd ed. Malden, Mass: Futura; 2005.
3. Kannan RY, Salacinski HJ, Butler PE, Hamilton G, Seifalian AM. Current status of prosthetic bypass grafts: a review. J Biomed Mater Res B Appl Biomater. 2005;74B:570-581.
4. Campbell CD, Brooks DH, Webster MW, Bahnson HT. Use of expanded microporous polytetrafluoroethylene for limb salvage: a preliminary report. Surgery. 1976;79:485-491.
5. Abbott WM, Green RM, Matsumoto T, Wheeler JR, Miller N, Veith FJ, Suggs WD, Hollier L, Money S, Garrett HE, Moore WS, Dean RH, Cronenwett JL, Carter S, Greenhalgh RM, ODonnell TF. Prosthetic above-knee femoropopliteal bypass grafting: results of a multicenter randomized prospective trial. J Vasc Surg. 1997;25:19-28.
6. Post S, Kraus T, Muller-Reinartz U, Weiss C, Kortmann H, Quentmeier A, Winkler M, Husfeldt KJ. Dacron vs polytetrafluoroethylene grafts for femoropopliteal bypass: a prospective randomised multicentre trial. Eur J Vasc Endovasc Surg. 2001;22:226-231.
7. Hobson RW, Odonnell JA, Jamil Z, Mehta K. Below-knee bypass for limb salvage: comparison of autogenous saphenous-vein, polytetrafluoroethylene, and composite Dacron-autogenous vein grafts. Arch Surg. 1980;115:833-837.
8. Seifalian AM, Salacinski HJ, Tiwari A, Edwards A, Bowald S, Hamilton G. In vivo biostability of a poly(carbonate-urea)urethane graft. Biomaterials. 2003;24:2549-2557.
9. Abbott WM, Megerman J, Hasson JE, Litalien G, Warnock DF. Effect of compliance mismatch on vascular graft patency. J Vasc Surg. 1987;5:376-382.
10. Stonebridge PA, Prescott RJ, Ruckley CV. Randomized trial comparing infrainguinal polytetrafluoroethylene bypass grafting with and without vein interposition cuff at the distal anastomosis. J Vasc Surg. 1997;26:543-550.
11. Griffiths GD, Nagy J, Black D, Stonebridge PA. Randomized clinical trial of distal anastomotic interposition vein cuff in infrainguinal polytetrafluoroethylene bypass grafting. Br J Surg. 2004;91:560-562.
12. Taylor RS, Loh A, Mcfarland RJ, Cox M, Chester JF. Improved technique for polytetrafluoroethylene bypass-grafting: long-term results using anastomotic vein patches. Br J Surg. 1992;79:348-354.
13. Batson RC, Sottiurai VS, Craighead CC. Linton patch angioplasty: an adjunct to distal bypass with polytetrafluoroethylene grafts. Ann Surg. 1984;199:684-693.
14. Ascer E, Gennaro M, Pollina RM, Ivanov M, Yorkovich WR, Ivanov M, Lorensen E. Complementary distal arteriovenous fistula and deep vein interposition: a five-year experience with a new technique to improve infrapopliteal prosthetic bypass patency. J Vasc Surg. 1996;24:134-143.
15. Syrek JR, Calligaro KD, Dougherty MJ, Raviola CA, Rua I, DeLaurentis DA. Do distal arteriovenous fistulae improve patency rates of prosthetic infrapopliteal arterial bypasses? Ann Vasc Surg. 1998;12:148-152.
16. Farrar DJ. Development of a prosthetic coronary artery bypass graft. Heart Surg Forum. 2000;3:36-40.
17. Kapfer X, Meichelboeck W, Groegler FM. Comparison of carbon-impregnated and standard ePTFE prostheses in extra-anatomical anterior tibial artery bypass: a prospective randomized multicenter study. Eur J Vasc Endovasc Surg. 2006;32:155-168.
18. Karrer L, Duwe J, Zisch AH, Khabiri E, Cikirikcioglu M, Napoli A, Goessl A, Schaffner T, Hess OM, Carrel T, Kalangos A, Hubbell JA, Walpoth BH. PPS-PEG surface coating to reduce thrombogenicity of small diameter ePTFE vascular grafts. Int J Artif Organs. 2005;28:993-1002.
19. Yoneyama T, Sugihara K, Ishihara K, Iwasaki Y, Nakabayashi N. The vascular prosthesis without pseudointima prepared by anti thrombogenic phospholipid polymer. Biomaterials. 2002;23:1455-1459.
20. Jordan SW, Faucher KM, Caves J, Apkarian R, Rele S, Sun X, Hanson S, Chaikof E. Fabrication of a phospholipid membrane-mimetic film on the luminal surface of an ePTFE vascular graft. Biomaterials. 2006;27:3473-3481.
21. Jordan SW, Haller CA, Sallach RE, Apkarian RP, Hanson SR, Chaikof EL. The effect of a recombinant elastin-mimetic coating of an ePTFE prosthesis on acute thrombogenicity in a baboon arteriovenous shunt. Biomaterials. 2007;28:1191-1197.
22. San Roman J, Bujan J, Bellon JM, Gallardo A, Escudero MC, Jorge E, de Haro J, Alvarez L, Castillo-Olivares JL. Experimental study of the antithrombogenic behavior of Dacron vascular grafts coated with hydrophilic acrylic copolymers bearing salicylic acid residues. J Biomed Mater Res. 1996;32:19-27.
23. Yang J, Motlagh D, Allen J, Webb A, Kibbe M, Aalami O, Kapadia M, Carroll T, Ameer GA. Modulating ePTFE vascular graft host response via citric acid-based biodegradable elastomers. Adv Mater. 2006;18:1493-1498.
24. Bosiers M, Deloose K, Verbist J, Schroe H, Lauwers G, Lansink W, Peeters P. Heparin-bonded expanded polytetrafluoroethylene vascular graft for femoropopliteal and femorocrural bypass grafting: 1-year results. J Vasc Surgery. 2006;43:313-318.
25. Tseng PY, Rele SS, Sun XL, Chaikof EL. Membrane-mimetic films containing thrombomodulin and heparin inhibit tissue factor-induced thrombin generation in a flow model. Biomaterials. 2006;27:2637-2650.
26. Wyers MC, Phaneuf MD, Rzucidlo EM, Contreras MA, LoGerfo FW, Quist WC. In vivo assessment of a novel Dacron surface with covalently bound recombinant hirudin. Cardiovasc Pathol. 1999;8:153-159.
27. Phaneuf MD, Szycher M, Berceli SA, Dempsey DJ, Quist WC, LoGerfo FW. Covalent linkage of recombinant hirudin to a novel ionic poly(carbonate) urethane polymer with protein binding sites: Determination of surface antithrombin activity. Artif Organs. 1998;22:657-665.
28. Heise M, Schmidmaier G, Husmann I, Heidenhain C, Schmidt J, Neuhaus P, Settmacher U. PEG-hirudin/iloprost coating of small diameter ePTFE grafts effectively prevents pseudointima and intimal hyperplasia development. Eur J Vasc Endovasc Surg. 2006;32:418-424.
29. Greco RS, Kim HC, Donetz AP, Harvey RA. Patency of a small vessel prosthesis bonded to tissue-plasminogen activator and iloprost. Ann Vasc Surg. 1995;9:140-145.
30. Greisler HP, Cziperle DJ, Kim DU, Garfield JD, Petsikas D, Murchan PM, Applegren EO, Drohan W, Burgess WH. Enhanced endothelialization of expanded polytetrafluoroethylene grafts by fibroblast growthfactor type-1 pretreatment. Surgery. 1992;112:244-255.
31. Gray JL, Kang SS, Zenni GC, Kim DU, Kim PI, Burgess WH, Drohan W, Winkles JA, Haudenschild CC, Greisler HP. FGF-1 affixation stimulates ePTFE endothelialization without intimal hyperplasia. J Surg Res. 1994;57:596-612.
32. Li C, Hill A, Imran M. In vitro and in vivo studies of ePTFE vascular grafts treated with P15 peptide. J Biomater Sci Polym Ed. 2005;16:875-891.
33. Cagiannos C, Abul-Khoudoud OR, DeRijk W, Shell DH, Jennings LK, Tolley EA, Handorf CR, Fabian TC. Rapamycin-coated expanded polytetrafluoroethylene bypass grafts exhibit decreased anastomotic neointimal hyperplasia in a porcine model. J Vasc Surg. 2005;42:980-987.
34. Lee BH, Nam HY, Kwon T, Kim SJ, Kwon GY, Jeon HJ, Lim HJLWK, Park JS, Ko JY, Kim DJ. Paclitaxel-coated expanded polytetrafluoroethylene haemodialysis grafts inhibit neointimal hyperplasia in porcine model of graft stenosis. Nephrol Dial Transplant. 2006;21:2432-2438.
35. Magometschnigg H, Kadletz M, Vodrazka M, Dock W, Grimm M, Grabenwoger M, Minar E, Staudacher M, Fenzl G, Wolner E. Prospective clinical-study with invitro endothelial-cell lining of expanded polytetrafluoroethylene grafts in crural repeat reconstruction. J Vasc Surg. 1992;15:527-535.
36. Deutsch M, Meinhart J, Fischlein T, Preiss P, Zilla P. Clinical autologous in vitro endothelialization of infrainguinal ePTFE grafts in 100 patients: a 9-year experience. Surgery. 1999;126:847-855.
37. Laube HR, Duwe J, Rutsch W, Konertz W. Clinical experience with autologous endothelial cell-seeded polytetrafluoroethylene coronary artery bypass grafts. J Thorac Cardiovasc Surg. 2000;120:134-141.
38. Heyligers JMM, Arts CHP, Verhagen HJM, de Groot PG, Moll FL. Improving small-diameter vascular grafts: From the application of an endothelial cell lining to the construction of a tissue-engineered blood vessel. Ann Vasc Surg. 2005;19:448-456.
39. Herring M, Gardner A, Glover J. Single-staged technique for seeding vascular grafts with autogenous endothelium. Surgery. 1978;84:498-504.
40. Zilla P, Fasol R, Deutsch M, Fischlein T, Minar E, Hammerle A, Krupicka O, Kadletz M. Endothelial-cell seeding of polytetrafluoroethylene vascular grafts in humans: a preliminary report. J Vasc Surg. 1987;6:535-541.
41. Herring M, Smith J, Dalsing M, Glover J, Compton R, Etchberger K, Zollinger T. Endothelial seeding of polytetrafluoroethylene femoral popliteal bypasses: the failure of low-density seeding to improve patency. J Vasc Surg. 1994;20:650-655.
42. Jensen N, Lindblad B, Bergqvist D. Endothelial-cell seeded Dacron aortobifurcated grafts: platelet deposition and long-term follow-up. J Cardiovasc Surg. 1994;35:425-429.
43. Fujita Y, Hong-De Wu M, Ishida A, Shi Q, Walker M, Hammond WP, Sauvage LR. Accelerated healing of Dacron grafts seeded by preclotting with autologous bone marrow blood. Ann Vasc Surg. 1999;13:402-412.
44. Bhattacharya V, McSweeney PA, Shi Q, Bruno B, Ishida A, Nash R, Storb RF, Sauvage LR, Hammond WP, Wu MHD. Enhanced endothelialization and microvessel formation in polyester grafts seeded with CD34(+) bone marrow cells. Blood. 2000;95:581-585.
45. Griese DP, Ehsan A, Melo LG, Kong DL, Zhang LN, Mann MJ, Pratt RE, Mulligan RC, Dzau VJ. Isolation and transplantation of autologous circulating endothelial cells into denuded vessels and prosthetic grafts: implications for cell-based vascular therapy. Circulation. 2003;108:2710-2715.
46. Rotmans JI, Heyligers JMM, Verhagen HJM, Velema E, Nagtegaal MM, de Kleijn DPV, de Groot FG, Stroes ESG, Pasterkamp G. In vivo cell seeding with anti-CD34 antibodies successfully accelerates endothelialization but stimulates intimal hyperplasia in porcine arteriovenous expanded polytetrafluoroethylene grafts. Circulation. 2005;112:12-18.
47. Meerbaum SO, Sharp WV, Schmidt SP. Lower extremity revascularization with polytertrafluoroethykebe grafts seeded with microvascular endothelial cells. In: Zilla P, Fasol R, Callow P, eds. Applied Cardiovascular Biology. Basel, Switzerland: Karger; 1992:107-119.
48. Williams SK. Human clinical trials of microvascular endothelial cell sodding. In: Zilla P, Greisler HP, eds. Tissue Engineering of Vascular Prosthetic Grafts. Austin, Tex: R.G. Landes; 1999:143-147.
49. Kibbe M, Billiar T, Tzeng E. Inducible nitric oxide synthase and vascular injury. Cardiovasc Res. 1999;43:650-657.
50. Keefer LK. Nitric oxide (NO)-and nitroxyl (HNO)-generating diazeniumdiolates (NONOates): emerging commercial opportunities. Curr Top Med Chem. 2005;5:625-634.
51. Smith DJ, Chakravarthy D, Pulfer S, Simmons ML, Hrabie JA, Citro ML, Saavedra JE, Davies KM, Hutsell TC, Mooradian DL, Hanson SR, Keefer LK. Nitric oxide-releasing polymers containing the [N(O)NO](-) group. J Med Chem. 1996;39:1148-1156.
52. Pulfer SK, Ott D, Smith DJ. Incorporation of nitric oxide-releasing crosslinked polyethyleneimine microspheres into vascular grafts. J Biomed Mater Res. 1997;37:182-189.
53. Mowery KA, Schoenfisch MH, Saavedra JE, Keefer LK, Meyerhoff ME. Preparation and characterization of hydrophobic polymeric films that are thromboresistant via nitric oxide release. Biomaterials. 2000;21:9-21.
54. Batchelor MM, Reoma SL, Fleser PS, Nuthakki VK, Callahan RE, Shanley CJ, Politis JK, Elmore J, Merz SI, Meyerhoff ME. More lipophilic dialkyldiamine-based diazeniumdiolates: synthesis, characterization, and application in preparing thromboresistant nitric oxide release polymeric coatings. J Med Chem. 2003;46:5153-5161.
55. Jun HW, Taite LJ, West JL. Nitric oxide-producing polyurethanes. Biomacromolecules. 2005;6:838-844.
56. Reynolds MM, Hrabie JA, Oh BK, Politis JK, Citro ML, Keefer LK, Meyerhoff ME. Nitric oxide releasing polyurethanes with covalently linked diazeniumdiolated secondary amines. Biomacromolecules. 2006;7:987-994.
57. Jourd'heuil D, Hallen K, Feelisch M, Grisham MB. Dynamic state of S-nitrosothiols in human plasma and whole blood. Free Radic Biol Med. 2000;28:409-417.
58. Tyurin VA, Tyurina YY, Liu SX, Bayir H, Hubel CA, Kagan VE. Quantitation of S-nitrosothiols in cells and biological fluids. Methods Enzymol. 2002;352:347-360.
59. Bohl KS, West JL. Nitric oxide-generating polymers reduce platelet adhesion and smooth muscle cell proliferation. Biomaterials. 2000;21:2273-2278.
60. Frost MC, Meyerhoff ME. Controlled photoinitiated release of nitric oxide from polymer films containing S-nitroso-N-acetyl-DL-penicillamine derivatized fumed silica filler. J Am Chem Soc. 2004;126:1348-1349.
61. Reynolds MM, Frost MC, Meyerhoff ME. Nitric oxide-releasing hydrophobic polymers: preparation, characterization, and potential biomedical applications. Free Radic Biol Med. 2004;37:926-936.
62. Gappa-Fahlenkamp H, Duan X, Lewis RS. Analysis of immobilized L-cysteine on polymers. J Biomed Mater Res A. 2004;71A:519-527.
63. Spaulding C, Daemen J, Boersma E, Cutlip DE, Serruys PW. A pooled analysis of data comparing sirolimus-eluting stents with bare-metal stents. N Engl J Med. 2007;356:989-997.
64. Lagerqvist B, James SK, Stenestrand U, Lindback J, Nilsson T, Wallentin L. Long-term outcomes with drug-eluting stents versus bare-metal stents in Sweden. N Engl J Med. 2007;356:1009-1019.
65. Maisel WH. Unanswered questions: drug-eluting stents and the risk of late thrombosis. N Engl J Med. 2007;356:981-984.